Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Executive Changes (Jun 26, 2026)

Reports
Leadership Changes·Shareholder Matters·Exhibits & Filings
Filing Date
Filed June 26, 2026
Period End
June 22, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed June 26, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. filed this Form 8-K on June 26, 2026 to report the results of its 2026 Annual Meeting of Stockholders, held June 22, 2026.

Of the 195,806,242 shares entitled to vote, 175,706,357 were present in person or by proxy. Dr. Randal W. Scott resigned from the Board of Directors effective June 22, 2026, upon completing his term as a Class I director.

The filing states that his resignation was not due to any disagreement with the Company on its operations, policies or practices. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting: James C. Momtazee, Frank P.

McCormick, Ph.D., and Hannah A. Valantine, M.D. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 152,949,577 votes for, 6,938,080 against and 1,219,213 abstentions.

They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 175,420,234 votes for and 203,310 against. Stockholders also approved an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, which increases the shares reserved for issuance by 2,000,000. That proposal received 132,402,786 votes for and 27,350,537 against.

On the frequency of future say-on-pay votes, stockholders favored an annual vote, with 154,371,970 votes for every 1 Year, compared with 5,199,700 for 2 Years and 1,467,447 for 3 Years. Following the Board's recommendation and consistent with that preference, the Company plans to hold these advisory votes every year. The amended and restated plan is filed as Exhibit 10.1.

Key Highlights

  1. Dr. Randal W. Scott resigned from the Board effective June 22, 2026, when his Class I term ended; the filing states the resignation involved no disagreement with the Company.
  2. Three Class I directors were elected to serve until the 2029 Annual Meeting: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D.
  3. Stockholders approved, on an advisory basis, the compensation of the named executive officers, with 152,949,577 votes for and 6,938,080 against.
  4. Stockholders favored an annual advisory say-on-pay vote (154,371,970 votes for every 1 Year), and the Company plans to hold these votes every year.
  5. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal 2026, with 175,420,234 votes for and 203,310 against.
  6. Stockholders approved an amendment and restatement of the 2021 Amended and Restated Stock Option and Incentive Plan that increases the shares reserved for issuance by 2,000,000, with 132,402,786 votes for and 27,350,537 against.
  7. The filing reports 14,599,487 broker non-votes on the director election, say-on-pay and equity plan proposals.

Frequently Asked Questions

  1. Why did Dr. Randal W. Scott leave the Board?

    Dr. Scott resigned as a Class I director upon completing his term, effective June 22, 2026, the date of the Annual Meeting. The filing states that his resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

  2. Who was elected to the Board at the 2026 Annual Meeting, and for how long?

    Stockholders elected James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D. as Class I directors. They will serve until the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Momtazee received 156,790,852 votes for and 4,316,018 withheld, McCormick received 153,020,532 for and 8,086,338 withheld, and Valantine received 129,081,930 for and 32,024,940 withheld.

  3. How did stockholders vote on executive pay and how often will the Company hold say-on-pay votes?

    Stockholders approved the named executive officer compensation on an advisory basis, with 152,949,577 votes for, 6,938,080 against and 1,219,213 abstentions. On frequency, 154,371,970 votes favored every 1 Year, 5,199,700 favored 2 Years and 1,467,447 favored 3 Years. The Board recommended, and the Company plans, annual advisory votes.

  4. What changed in the 2021 equity incentive plan?

    Stockholders approved an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. Among other things, it increases the number of shares reserved for issuance by 2,000,000. The proposal received 132,402,786 votes for, 27,350,537 against and 1,353,547 abstentions, and the plan in the form approved is filed as Exhibit 10.1.

  5. Who is the Company's independent auditor for 2026?

    Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 175,420,234 for, 203,310 against and 82,813 abstentions, with no broker non-votes.